A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata (ALLEGRO-100)

Study type: Clinical Trials Posting date: 10/20/2026 Last updated: 10/20/2026 Status: Active Phase: Phase 3 Country: Multiple Eligibility:

This clinical trial will determine if a study medicine is safe and tolerable, and if it can help hair grow back in people 12 years of age or older with moderate alopecia areata.

This study is seeking participants who:

  • Are 12 years of age or older (Part 1)
  • Are 12 to less than 18 years (Part 2)
  • Have a diagnosis of alopecia areata
  • Have lost 50% or more of the hair on their scalp
  • Do not have any other conditions that causes hair loss
  • Are willing to stop all other treatments that they may be taking for alopecia areata

Learn more (English)

Learn more (Spanish)

Drug: ritlecitinib or placebo Administration: oral Sponsor: Pfizer Sponsor Link: Click here ClinicalTrials.gov link: Click here Location: Multiple locations


Description:

This clinical trial will determine if a study medicine is safe and tolerable, and if it can help hair grow back in people 12 years of age or older with moderate alopecia areata.

This clinical trial is enrolling adults and adolescents 12 years of age or older who are generally healthy (or have stable medical conditions), have been diagnosed with alopecia areata, do not have hair loss caused by any other conditions, and have been experiencing hair loss for longer than 6 months but less than 10 years.

Participants will receive care from a team of dedicated medical professionals while contributing to research that could help people around the world.

Ritlecitinib is approved in many countries at a dose of 50 mg (milligram) taken by mouth once a day for the treatment of patients 12 years and older with severe alopecia areata. This study will look at both the 50 mg dose and a 100 mg dose.